RxDoctor Payments Data

Robin Savar, DO

Family Medicine · Reading, PANPI 1013915990

Payments from drug & device makers

$184in general payments, 2019–2025

Across 13 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$29
  • GSK$27
  • Supernus Pharmaceuticals, Inc.$21
  • Novo Nordisk$16
  • Amgen$16
  • Kowa Pharmaceuticals America, Inc.$14
  • plus $60 from 5 others

What the payments were for

  • Food & beverage$184100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$184 in reported general payments places this provider in the 40th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$81,461
Medicare patients
279
Services billed
920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$110,052
JardianceEmpagliflozin59$49,188
EliquisApixaban32$42,199
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$29,381
Breo ElliptaFluticasone/Vilanterol35$19,098
TrulicityDulaglutide21$19,072
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$11,339
Tresiba Flextouch U-100Insulin Degludec17$10,026
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$6,917
Atorvastatin Calcium467$5,004
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,844
DiovanValsartan12$3,488
Levothyroxine Sodium297$3,299
Bisoprolol Fumarate76$3,265
Metoprolol Succinate177$2,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$110,05291 claims
Boehringer IngelheimJardiance$11$49,18859 claims
GSKTrelegy Ellipta, Breo Ellipta$27$48,47981 claims
Lilly USA, LLCTrulicity$11$19,07221 claims
NovartisDiovan$29$3,48812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →